Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Experimental and Molecular Pathology|June 28, 2025
Polymerase Ѳ inhibitors combinations with approved and investigational agents in patient-derived tumor multi-cell type (mct) spheroidsBeverly A Teicher, Thomas S Dexheimer, Li Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancerJohn R Goffin, Ian C Anderson, Jeffrey G Supko, et al.
Plos One|February 21, 2012
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)Chandrajit P Raut, Yves Boucher, Dan G Duda, et al.
The Lancet. Oncology|June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialTanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
JCO Precision Oncology|February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid TumorsYiduo Hu, Azeet Narayan, Yunshan Xu, et al.
JCO Precision Oncology|February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket StudyJulio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Gynecologic Oncology|June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancersJoyce F Liu, Michael Gordon, Jennifer Veneris, et al.
JCO Precision Oncology|September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
The Oncologist|June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRASChristopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Pageof 4